David J Brooks

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. doi request reprint Imaging non-motor aspects of Parkinson's disease
    David J Brooks
    Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK
    Prog Brain Res 184:205-18. 2010
  2. pmc Neuroimaging in Parkinson's disease
    David J Brooks
    Medical Research Council Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN, United Kingdom
    NeuroRx 1:243-54. 2004
  3. pmc Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
    D J Brooks
    Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    J Neurol Neurosurg Psychiatry 74:1071-9. 2003
  4. ncbi request reprint PET studies on the function of dopamine in health and Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK
    Ann N Y Acad Sci 991:22-35. 2003
  5. doi request reprint Proposed neuroimaging criteria for the diagnosis of multiple system atrophy
    David J Brooks
    Division of Neuroscience, Faculty of Medicine, Imperial College London, London, United Kingdom
    Mov Disord 24:949-64. 2009
  6. doi request reprint The role of structural and functional imaging in parkinsonian states with a description of PET technology
    David J Brooks
    Division of Neuroscience and Medical Research Council Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Semin Neurol 28:435-45. 2008
  7. ncbi request reprint Imaging end points for monitoring neuroprotection in Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:S110-8; discussion S118-9. 2003
  8. pmc Diagnosis and management of atypical parkinsonian syndromes
    David J Brooks
    Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London UK
    J Neurol Neurosurg Psychiatry 72:I10-I16. 2002
  9. doi request reprint Technology insight: imaging neurodegeneration in Parkinson's disease
    David J Brooks
    Faculty of Medicine at Imperial College, London, UK
    Nat Clin Pract Neurol 4:267-77. 2008
  10. ncbi request reprint Imaging non-dopaminergic function in Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Mol Imaging Biol 9:217-22. 2007

Detail Information

Publications135 found, 100 shown here

  1. doi request reprint Imaging non-motor aspects of Parkinson's disease
    David J Brooks
    Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK
    Prog Brain Res 184:205-18. 2010
    ..Finally the discordance between the development of functional changes in PD and Braak staging is highlighted...
  2. pmc Neuroimaging in Parkinson's disease
    David J Brooks
    Medical Research Council Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN, United Kingdom
    NeuroRx 1:243-54. 2004
    ..It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD...
  3. pmc Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
    D J Brooks
    Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    J Neurol Neurosurg Psychiatry 74:1071-9. 2003
    ....
  4. ncbi request reprint PET studies on the function of dopamine in health and Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK
    Ann N Y Acad Sci 991:22-35. 2003
    ..In this review, the insight that PET has given us concerning the role of dopamine in motor control is presented, and the functional substrates underlying PD symptomatologies are discussed...
  5. doi request reprint Proposed neuroimaging criteria for the diagnosis of multiple system atrophy
    David J Brooks
    Division of Neuroscience, Faculty of Medicine, Imperial College London, London, United Kingdom
    Mov Disord 24:949-64. 2009
    ..It is concluded that, although neuroimaging biomarkers provide valuable supportive data alongside clinical assessments, it is not possible to use them as surrogate markers...
  6. doi request reprint The role of structural and functional imaging in parkinsonian states with a description of PET technology
    David J Brooks
    Division of Neuroscience and Medical Research Council Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Semin Neurol 28:435-45. 2008
    ..Finally, the value of functional imaging as a biomarker for following the progression of PD and for understanding mechanisms of dementia when present is debated...
  7. ncbi request reprint Imaging end points for monitoring neuroprotection in Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:S110-8; discussion S118-9. 2003
    ..It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD...
  8. pmc Diagnosis and management of atypical parkinsonian syndromes
    David J Brooks
    Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London UK
    J Neurol Neurosurg Psychiatry 72:I10-I16. 2002
  9. doi request reprint Technology insight: imaging neurodegeneration in Parkinson's disease
    David J Brooks
    Faculty of Medicine at Imperial College, London, UK
    Nat Clin Pract Neurol 4:267-77. 2008
    ..The contribution of inflammatory processes to the pathology of PD is discussed, as are the various possible mechanisms that lead to coexistent dementia and depression...
  10. ncbi request reprint Imaging non-dopaminergic function in Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Mol Imaging Biol 9:217-22. 2007
    ..In addition, neuronal loss in PD is associated with microglial activation. The role of microglia in driving the disease process remains uncertain. This review presents and discusses current findings in these areas...
  11. doi request reprint Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease
    David J Brooks
    Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    J Neural Transm 115:843-9. 2008
    ..The mean daily dose of levodopa did not increase over the 5-year follow-up period. Long-term therapy with levodopa/DDCI and entacapone was well-tolerated...
  12. doi request reprint Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Imperial College, London, United Kingdom
    Mov Disord 24:S742-7. 2009
    ..Anti-amyloid strategies could be a relevant approach for slowing dementia in a number of DLB and PDD cases...
  13. ncbi request reprint Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional
    D J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Eur Neurol 53:197-202. 2005
    ..e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations...
  14. ncbi request reprint Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model
    David J Brooks
    Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Wien Klin Wochenschr 118:570-2. 2006
  15. doi request reprint Examining Braak's hypothesis by imaging Parkinson's disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Mov Disord 25:S83-8. 2010
    ....
  16. ncbi request reprint Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease
    D J Brooks
    MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK
    J Neurol 247:II11-8. 2000
    ..PET currently has the greater spatial resolution and provides the added advantages that it also allows extra-striatal dopaminergic function to be monitored...
  17. doi request reprint Imaging approaches to Parkinson disease
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    J Nucl Med 51:596-609. 2010
    ..Finally, PET can detect widespread brain inflammation in PD. This review discusses the role of structural and functional imaging for diagnosing and managing different parkinsonian syndromes...
  18. ncbi request reprint Imaging in Parkinson's disease: the role of monoamines in behavior
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College London, United Kingdom
    Biol Psychiatry 59:908-18. 2006
    ..Novel markers of amyloid plaque load will also help clarify the etiology of dementia in PD...
  19. pmc Positron emission tomography and single-photon emission computed tomography in central nervous system drug development
    David J Brooks
    Medical Research Council Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN, United Kingdom
    NeuroRx 2:226-36. 2005
    ....
  20. ncbi request reprint Microglial activation in presymptomatic Huntington's disease gene carriers
    Yen F Tai
    MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 130:1759-66. 2007
    ..PK PET may be a useful marker of active subclinical disease and a means of investigating the efficacy of neuroprotection strategies in PGCs...
  21. doi request reprint Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers
    Nicola Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Neurobiol Dis 37:356-61. 2010
    ..It is an early event in HD pathophysiology and could contribute to the impairment in neuropsychological performance in these patients...
  22. ncbi request reprint A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195
    Alexander N Anderson
    Department of Clinical Neuroscience, Division of Neuroscience and Mental Health, Imperial College London, UK
    Neuroimage 36:28-37. 2007
    ..The reference-to-target ratio and the Logan graphical approach were significantly less reliable and less sensitive...
  23. doi request reprint Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study
    Paul Edison
    MRC Clinical Sciences Centre, Cyclotron Building Hammersmith Hospital, Imperial College London, UK
    Neurobiol Dis 32:412-9. 2008
    ..MMSE scores in AD subjects correlated with levels of cortical microglial activation but not with amyloid load. The inverse correlation between MMSE and microglial activation is compatible with a role of microglia in neuronal damage...
  24. doi request reprint In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study
    Nicola Pavese
    MRC Clinical Science Centre and Division of Neuroscience and Mental Health, Imperial College, London, UK
    Exp Neurol 222:120-4. 2010
    ..These findings suggest that parkin patients and IPD patients with similar striatal dysfunction have different patterns of monoaminergic involvement, with more widespread dysfunction in IPD...
  25. ncbi request reprint Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism
    Christoph Scherfler
    MRC Clinical Science Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 127:1332-42. 2004
    ..Cortical reductions in D2 binding may contribute to the behavioural problems reported in parkin patients...
  26. ncbi request reprint Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease
    Michele T M Hu
    MRC Clinical Sciences Centre, Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:299-305. 2006
    ....
  27. ncbi request reprint Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [(11)C]diprenorphine test-retest data
    Alexander Hammers
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, DuCane Road, London, UK
    Neuroimage 38:82-94. 2007
    ..86) but unacceptably low for VOI-derived VD estimates at the low doses of injected radioactivity (0.24/0.04). Our data can inform the choice of methodology for a given biological problem...
  28. ncbi request reprint Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations
    Christoph Scherfler
    MRC Clinical Science Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:783-8. 2006
    ..Parkin-positive patients appear to have a greater susceptibility to the exposure to dopaminergic medication than IPD patients, which in turn might be an indirect effect of their genetic mutation...
  29. ncbi request reprint In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy
    Alexander Gerhard
    MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, and National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Mov Disord 21:89-93. 2006
    ..11C](R)-PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP...
  30. doi request reprint Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study
    Nicola Pavese
    MRC Clinical Science Centre, Imperial College, London, United Kingdom nicola pavese csc mrc ac uk
    Mov Disord 24:2260-6. 2009
    ..Although subclinical reductions of striatal (18)F-dopa uptake are common in carriers of a single parkin mutation their slow rate of progression suggests that few if any of these will develop clinical parkinsonism...
  31. doi request reprint Cognitive deficits and striato-frontal dopamine release in Parkinson's disease
    Nobukatsu Sawamoto
    Division of Neuroscience, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, UK
    Brain 131:1294-302. 2008
    ..In contrast, mesocortical dopaminergic transmission appears well preserved in early PD patients...
  32. doi request reprint Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK
    Sci Transl Med 2:38ra46. 2010
    ..Our observations suggest strategies for avoiding and treating graft-induced dyskinesias that result from cell therapies for Parkinson's disease with fetal tissue or stem cells...
  33. doi request reprint Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Mov Disord 26:1997-2003. 2011
    ..Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft-induced dyskinesias...
  34. ncbi request reprint A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study
    Alan L Whone
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    J Nucl Med 45:1135-45. 2004
    ..To our knowledge, this is the first time such a centralized approach has been employed with (18)F-DOPA PET and this descriptive basic science article outlines the methods used...
  35. ncbi request reprint Compulsive drug use linked to sensitized ventral striatal dopamine transmission
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Ann Neurol 59:852-8. 2006
    ..We aimed to evaluate levodopa-induced dopamine neurotransmission in the striatum of patients with DDS compared with PD control patients...
  36. ncbi request reprint Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
    Alan L Whone
    Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 54:93-101. 2003
    ..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
  37. doi request reprint Brain monoamine systems in multiple system atrophy: a positron emission tomography study
    Stephanie J Lewis
    Centre for Neuroscience, Dept of Medicine, Imperial College London, Hammersmith Hospital, London, UK
    Neurobiol Dis 46:130-6. 2012
    ..In contrast to PD, there was no evidence of early compensatory increases in regional 18F-dopa uptake...
  38. ncbi request reprint Factors affecting the clinical outcome after neural transplantation in Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 128:2977-86. 2005
    ..Finally, our data provide evidence that long-term immunosuppression can be withdrawn without interfering with graft survival or the motor recovery induced by transplantation...
  39. ncbi request reprint Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space
    Alexander Hammers
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Hum Brain Mapp 28:34-48. 2007
    ..Applications include probabilistic determination of location in group studies, automatic labeling of new scans, and detection of anatomical abnormalities in patients...
  40. doi request reprint Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK
    Sci Transl Med 4:128ra41. 2012
    ....
  41. ncbi request reprint Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus
    R Laila Ahsan
    Division of Neuroscience, Faculty of Medicine, Imperial College, and MRC Clinical Sciences Centre, Hammersmith Hospital, DuCane Road, London, UK
    Neuroimage 38:261-70. 2007
    ..We present a comprehensive assessment of thalamic and basal ganglia volumetric and geometric data in both native and stereotaxic spaces. Probabilistic maps in MNI/ICBM152 space will allow accurate localization in group analyses...
  42. doi request reprint Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study
    Marios Politis
    Department of Clinical Neurosciences and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK
    Hum Brain Mapp 32:258-70. 2011
    ..These data suggest that pathologically activated microglia in AST and other areas related to cognitive function, maybe better predictors of clinical onset and stresses the importance of early cognitive assessment in HD...
  43. ncbi request reprint [11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling?
    Alexander Hammers
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
    J Cereb Blood Flow Metab 28:207-16. 2008
    ..Full quantification with an image-independent input should ideally be used in the evaluation of FMZ PET; at least in TLE, intrasubject correlations do not predict equivalent clinical usefulness...
  44. doi request reprint Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study
    Nicola Pavese
    Centre for Neuroscience, Department of Medicine, Imperial College London, UK
    Neuroimage 56:1463-8. 2011
    ..When assessing the efficacy of novel neuroprotective agents on nigrostriatal dysfunction in PD, (18)F-dopa PET could provide supplementary information concerning function of extrastriatal monoaminergic structures...
  45. pmc Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia
    Paul Edison
    Centre of Neuroscience, Department of Medicine, Imperial College London, London, UK
    Neuropsychopharmacology 38:938-49. 2013
    ..Significant microglial activation may be a factor in driving the disease process in PDD. Given this, agents that affect microglial activation could have an influence on disease progression...
  46. ncbi request reprint Upregulation of opioid receptor binding following spontaneous epileptic seizures
    Alexander Hammers
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 130:1009-16. 2007
    ..This study provides direct human in vivo evidence for changes in opioid receptor availability over a time course of hours following spontaneous seizures, emphasizing an important role of the opioid system in seizure control...
  47. ncbi request reprint Imaging microglial activation in Huntington's disease
    Yen F Tai
    Division of Neuroscience and Psychological Medicine, Hammersmith Hospital, Imperial College London, UK
    Brain Res Bull 72:148-51. 2007
    ..Further longitudinal studies are needed to fully elucidate this link...
  48. ncbi request reprint Reference and target region modeling of [11C]-(R)-PK11195 brain studies
    Federico E Turkheimer
    Division of Neuroscience, Department of Clinical Neuroscience, Imperial College London, London, United Kingdom
    J Nucl Med 48:158-67. 2007
    ....
  49. ncbi request reprint Endogenous dopamine release after pharmacological challenges in Parkinson's disease
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:647-53. 2003
    ..Our data also show that the capacity to release normal DA levels in prefrontal areas after a pharmacological challenge is preserved in severe stages of the disease...
  50. ncbi request reprint In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
    Alexander Gerhard
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, UK
    Neurobiol Dis 21:404-12. 2006
    ..The absence of significant longitudinal changes suggests that microglia are activated early in the disease process, and levels then remain relatively static, possibly driving the disease via cytokine release...
  51. ncbi request reprint The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study
    Sarah von Spiczak
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK
    Brain 128:906-17. 2005
    ..We therefore discuss a possible role for opioids in the pathophysiology of RLS with respect to sensory and motor symptoms...
  52. doi request reprint The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study
    Kit Wu
    Centre for Neuroscience, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
    Brain 135:2449-57. 2012
    ....
  53. ncbi request reprint Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
    Nicola Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 126:1127-35. 2003
    ..This probably reflects both contributions from other affected brain structures and high variance in these measures...
  54. doi request reprint Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study
    Robert Y Moore
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Cyclotron Building, Imperial College, Hammersmith Hospital, London W12 ONN, UK
    Neurobiol Dis 29:381-90. 2008
    ..The red nucleus, subthalamus, ventral thalamus and pineal gland were also eventually involved. These findings provide a further basis for understanding the complex pathophysiology of PD in vivo and complement pathological studies...
  55. doi request reprint Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility
    Paul Edison
    Medical Research Council Clinical Sciences Centre and Division of Neuroscience, Hammersmith Hospital, Imperial College London, UK
    Neuroimage 48:329-38. 2009
    ..Patlak analysis of [11C]PIB binding was the least reproducible...
  56. doi request reprint Quantification of opioid receptor availability following spontaneous epileptic seizures: correction of [11C]diprenorphine PET data for the partial-volume effect
    Colm J McGinnity
    Centre for Neuroscience, Department of Medicine, Imperial College London, London W12 0NN, UK
    Neuroimage 79:72-80. 2013
    ..Denoising, resolution recovery and precise anatomical segmentation can extract valuable information from PET studies that would be missed with conventional post-processing procedures...
  57. ncbi request reprint Safety and tolerability of COMT inhibitors
    David J Brooks
    MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, United Kingdom
    Neurology 62:S39-46. 2004
    ..With over 300,000 patient-years of exposure, levodopa combined with entacapone can be considered safe and well tolerated...
  58. doi request reprint Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD
    Clare Loane
    Department of Medicine, Division of Brain Sciences, Hammersmith Hospital, Imperial College London, UK
    Neurology 80:1850-5. 2013
    ..It is suggested that serotonergic dysfunction could have a role in tremor development...
  59. pmc Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation
    Lucy J Garvey
    Department of Medicine, Imperial College London, London, United Kingdom
    PLoS ONE 7:e38980. 2012
    ..The aim of this study was to investigate the effect of acute HCV infection upon cerebral function and microglial cell activation in HIV-infected individuals...
  60. doi request reprint Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
    Imtiaz Ahmed
    Centre for Neuroscience, Imperial College, London, UK
    Brain 134:979-86. 2011
    ..They support the hypothesis that blockade of glutamate transmission may have a place in the management of disabling dyskinesias in Parkinson's disease...
  61. doi request reprint Inflammation after trauma: microglial activation and traumatic brain injury
    Anil F Ramlackhansingh
    Centre for Neuroscience, Department of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK
    Ann Neurol 70:374-83. 2011
    ..In this study, we investigate whether an inflammatory response to TBI persists, and whether this response relates to structural brain abnormalities and cognitive function...
  62. ncbi request reprint Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study
    Naheed L Khan
    Department of Molecular Pathogenesis, Institute of Neurology, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Ann Neurol 52:849-53. 2002
    ..The subclinical loss of striatal dopamine storage capacity found in the PARK6 carriers implies that the unidentified gene on the short arm of chromosome 1 exhibits either haploinsufficency or a dominant negative effect...
  63. doi request reprint Serotonergic mediated body mass index changes in Parkinson's disease
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Hammersmith Hospital, Imperial College London, London, UK
    Neurobiol Dis 43:609-15. 2011
    ..The regions implicated are the rostral raphe nuclei and its connections to limbic and cognitive areas. It is conceivable that 5-HT agents could help alleviate abnormal changes in BMI in PD...
  64. ncbi request reprint Reward processing in health and Parkinson's disease: neural organization and reorganization
    Ines K Goerendt
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Cereb Cortex 14:73-80. 2004
    ..We interpret these relative increases in cerebellar activation as evidence for the presence of compensatory neural mechanisms in unmedicated PD patients...
  65. ncbi request reprint Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
    Ines K Goerendt
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Brain 126:312-25. 2003
    ..These findings confirm that striatal dopamine release is a component of movement sequencing and show that dopamine release can be detected in early Parkinson's disease during a behavioural manipulation...
  66. ncbi request reprint Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study
    Naheed L Khan
    MRC Clinical Sciences Centre, and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Brain 125:2248-56. 2002
    ..However, the two carriers scanned twice showed no progression over a 7-year period. The slower rate of disease progression in parkin patients may explain the near normal longevity of these patients with young onset parkinsonism...
  67. ncbi request reprint Cardiovascular effects of methamphetamine in Parkinson's disease patients
    Nicola Pavese
    MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College Hammersmith Hospital Campus, London, United Kingdom
    Mov Disord 19:298-303. 2004
    ..These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment...
  68. ncbi request reprint 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
    Roberto Ceravolo
    MRC Cyclotron Unit, Hammersmith Hospital, Institute of Neurology, London, UK
    Synapse 43:201-7. 2002
    ..0059 +/- 0.0028) in the absence of this drug. These findings are compatible with clinical doses of tolcapone having a significant blocking effect on peripheral and central COMT but not DDC activity in PD...
  69. ncbi request reprint Opioid binding in DYT1 primary torsion dystonia: an 11C-diprenorphine PET study
    Alan L Whone
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 19:1498-503. 2004
    ..We conclude that aberrant opioid transmission is unlikely to be present in DYT1-PTD and altered opioid transmission is not a common mechanism underlying all disorders of involuntary movement...
  70. ncbi request reprint An imaging study of parkinsonism among African-Caribbean and Indian London communities
    Michele T M Hu
    Movement Disorders Unit, Department of Neurology, Guy s, King s and St Thomas School of Medicine and the Institute of Psychiatry, King s College London, London, United Kingdom
    Mov Disord 17:1321-8. 2002
    ..Our results suggest the atypical parkinsonian phenotype seen in African-Caribbean and Indian patients represents a levodopa-refractory form of PD separate from MSA or PSP in most patients...
  71. doi request reprint Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study
    Marios Politis
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Cyclotron Building, Hammersmith Hospital, Imperial College London, DuCane Road W12 0NN, London, UK
    Exp Neurol 214:112-6. 2008
    ..Our results provide further evidence of dopaminergic dysfunction in the hypothalamus in PD, and this may contribute to the development of sleep, endocrine and autonomic disorders...
  72. pmc Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study
    Yen F Tai
    Faculty of Medicine, Centre for Neuroscience, Hammersmith Campus, Imperial College London, London, UK
    Neuropsychopharmacology 36:735-43. 2011
    ..Further longitudinal studies are required to elucidate the significance of these findings as they may have important public health implications...
  73. pmc Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
    P K Morrish
    MRC Cyclotron Unit Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 64:314-9. 1998
    ....
  74. ncbi request reprint Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study
    N Pavese
    MRC Clinical Sciences Centre and Division of Neurosciences, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Neurology 67:1612-7. 2006
    ..To evaluate the relationship between clinical improvement and in vivo synaptic dopamine (DA) release after a single oral dose of levodopa (LD) in patients with advanced Parkinson disease (PD)...
  75. ncbi request reprint Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study
    Y F Tai
    MRC Clinical Sciences Centre and Division of Neurosciences, Hammersmith Hospital, Imperial College London, United Kingdom
    J Neural Transm 114:337-40. 2007
    ..This is the first in vivo documentation of cortical dopaminergic deficiency in PSP. Reduced striatal (18)F-dopa uptake in susceptible relatives may predict later clinical disease...
  76. ncbi request reprint A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study
    J S Rakshi
    MRC Clinical Sciences Centre Imperial College School of Medicine, Hammersmith Hospital, London, UK
    J Neural Transm 109:1433-43. 2002
    ..To study the relative rates of progression of early Parkinson's disease (PD) in patients started on a dopamine agonist, ropinirole, or L-dopa...
  77. ncbi request reprint Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe
    Alexander Hammers
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Hum Brain Mapp 19:224-47. 2003
    ..Its potential applications range from the automatic labeling of new scans to the detection of anatomical abnormalities in patients. Further data can be extracted from the atlas for the detailed analysis of individual structures...
  78. ncbi request reprint In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration
    Alexander Gerhard
    MRC Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom
    Mov Disord 19:1221-6. 2004
    ....
  79. ncbi request reprint New developments of brain imaging for Parkinson's disease and related disorders
    Paola Piccini
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Imperial College, Hammersmith Hospital, London, United Kingdom
    Mov Disord 21:2035-41. 2006
    ..This review focuses on these recent advances in neuroimaging technology and their use for the diagnosis and assessment of PD and other parkinsonian disorders...
  80. doi request reprint Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction
    Nicola Pavese
    Department of Medicine, Centre for Neuroscience, Imperial College, London, UK
    Brain 133:3434-43. 2010
    ..These findings imply that strategies to increase brain level of serotonin would be a rational approach for relieving fatigue symptoms in Parkinson's disease and may also be relevant to alleviating fatigue in other clinical conditions...
  81. ncbi request reprint Plasticity of the nigropallidal pathway in Parkinson's disease
    Alan L Whone
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    Ann Neurol 53:206-13. 2003
    ....
  82. pmc Positron emission tomography imaging of transplant function
    David J Brooks
    Medical Research Council Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 ONN, United Kingdom
    NeuroRx 1:482-91. 2004
    ....
  83. pmc Microglial activation and amyloid deposition in mild cognitive impairment: a PET study
    A Okello
    Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, London, UK
    Neurology 72:56-62. 2009
    ..They are, therefore, a potential therapeutic target in both AD and its prodrome amnestic mild cognitive impairment (MCI)...
  84. ncbi request reprint In-vivo measurement of activated microglia in dementia
    A Cagnin
    MRC Cyclotron Unit, Imperial College, Faculty of Medicine, Division of Neuroscience and Psychological Medicince, Hammersmith Hospital, London, UK
    Lancet 358:461-7. 2001
    ..INTERPRETATION: In-vivo detection of increased [11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms, suggests that microglial activation is an early event in the pathogenesis of the disease...
  85. pmc The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
    P Piccini
    Department of Neurology, Imperial College, School of Medicine, Hammersmith Hospital, London, UK
    J Neurol Neurosurg Psychiatry 68:589-94. 2000
    ....
  86. ncbi request reprint Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline
    M T Hu
    Robert Steiner MR Unit, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom
    J Neural Transm 108:571-80. 2001
    ....
  87. doi request reprint Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease
    I Reuter
    Academic Department of Neuroscience, Kings College Hospital, London, UK
    J Neurol Neurosurg Psychiatry 79:948-51. 2008
    ..The other patient did not improve clinically or radiologically. Our results indicate that striatal transplantation in HD may be beneficial but further studies are needed to confirm this...
  88. ncbi request reprint Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography
    P Piccini
    MRC Clinical Science Center, Imperial College School of Medicine, Hammersmith Hospital, DuCane Road, W12 ONN London, England
    Arch Neurol 58:1846-51. 2001
    ..The rarity of reports of familial PSP may be attributed in part to an inability to detect subclinical disease in affected relatives who subsequently die before symptoms clinically develop...
  89. ncbi request reprint Microglial activation correlates with severity in Huntington disease: a clinical and PET study
    N Pavese
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Neurology 66:1638-43. 2006
    ..In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process...
  90. ncbi request reprint Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET
    M R Turner
    Department of Neurology, Institute of Psychiatry, King s College, De Crespigny Park, London, UK
    Brain 128:1323-9. 2005
    ..This study provides evidence for differences in the distribution of reduced cortical [11C]flumazenil binding in homD90A compared with sALS patients. We hypothesize that this might reflect differences in cortical neuronal vulnerability...
  91. pmc Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease
    A L Cheesman
    Medical Research Council Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    J Neurol Neurosurg Psychiatry 76:1204-10. 2005
    ..This study aimed to investigate the contribution of the dopaminergic system to performance on two executive tasks using (18)F-6-fluorodopa positron emission tomography ((18)F-dopa PET) in PD subjects with early cognitive changes...
  92. ncbi request reprint Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
    D J Brooks
    MRC Faculty of Medicine, Imperial College, London, UK
    Exp Neurol 184:S68-79. 2003
    ..The criteria and each of the three imaging techniques mentioned above were reviewed, and the results of that meeting are presented...
  93. ncbi request reprint Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study
    P Edison
    MRC Clinical Sciences Centre and Division of Neuroscience, Hammersmith Hospital, Imperial College London, London, UK
    Neurology 68:501-8. 2007
    ..To investigate the association between brain amyloid load in Alzheimer disease (AD) measured by [11C]PIB-PET, regional cerebral glucose metabolism (rCMRGlc) measured by [18F]FDG-PET, and cognition...
  94. ncbi request reprint [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy
    A Gerhard
    MRC Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial College, London, UK
    Neurology 61:686-9. 2003
    ..Providing an indicator of disease activity, [11C](R)-PK11195 PET can thus be used to characterize the in vivo neuropathology of MSA...
  95. ncbi request reprint Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study
    Robert Y Moore
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, DuCane Road, London W12 ONN, UK
    Brain Res 982:137-45. 2003
    ..These data indicate that 18F-DOPA PET can be used with detailed, anatomically based ROIs as a tool for in vivo analysis of regional changes in monoamine neuron systems throughout the brain in Parkinson's disease and other disorders...
  96. ncbi request reprint Assessment of Parkinson's disease with imaging
    David J Brooks
    MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Parkinsonism Relat Disord 13:S268-75. 2007
    ..The underlying pathological mechanisms leading to tremor, coexistent dementia and depression in PD are considered and the role of imaging as a biomarker for testing neuroprotective agents debated...
  97. ncbi request reprint The human premotor cortex is 'mirror' only for biological actions
    Yen F Tai
    Division of Neuroscience, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, Imperial College, London W12 0NN, United Kingdom
    Curr Biol 14:117-20. 2004
    ..This result indicates for the first time that in humans the mirror system is biologically tuned. This system appears to be the neural substrate for biological preference during action coding...
  98. ncbi request reprint STN stimulation alters pallidal-frontal coupling during response selection under competition
    Stephane Thobois
    Functional Neurosurgery Unit, Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, UK
    J Cereb Blood Flow Metab 27:1173-84. 2007
    ..This is the first direct evidence that STN stimulation significantly alters pallidal coupling with prefrontal, cingulate, and temporal cortices during performance of a task that requires response selection under competition...
  99. ncbi request reprint Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease
    Liory Fern-Pollak
    Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN, UK
    Neuropsychologia 42:1917-26. 2004
    ..This study aimed to clarify the role of dopaminergic medication in spatial working memory, and reinforcement-based associative learning in relation to clinical changes in motor function in early Parkinson's disease (PD)...
  100. ncbi request reprint Distributed neural actions of anti-parkinsonian therapies as revealed by PET
    I K Goerendt
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    J Neural Transm 113:75-86. 2006
    ..Our findings suggest that the two treatment methods may lead to symptomatic relief via both common and different sites of action...
  101. pmc Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study
    A Okello
    Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, UK
    Neurology 73:754-60. 2009
    ..Patients with amnestic mild cognitive impairment (MCI) represent an important clinical group as they are at increased risk of developing Alzheimer disease (AD). (11)C-PIB PET is an in vivo marker of brain amyloid load...